Navigation Links
Study: EBV Mononucleosis Risk Increased by Smoking and Family Size; polyDNA Recommends Gene-Eden-VIR Against the Latent EBV
Date:7/21/2013

Rochester, NY (PRWEB) July 21, 2013

A new study has shown that people living in large households or in families with smokers are at a significantly higher risk of Epstein Barr Virus (EBV) infection. EBV is well-known as the virus that can cause Mononucleosis, also known as the “kissing disease.”(1)

This rise in the risk of infection is due to the fact that smoking harms the immune system, allowing the EBV to attack the body and infect it more effectively. Further, people living in crowded homes have a higher chance of coming into contact with someone already infected with the virus. These crowded conditions can also lead to infectious mononucleosis since “Persons with infectious mononucleosis may be able to spread the infection to others for a period of weeks.” (CDC) (2)

The researchers wrote that “Environmental factors associated with socioeconomic status, such as household crowding or use of public transportation, could contribute directly to exposure risk. Suppressed immune function as a result of stress, poor nutrition, smoking, or other environmental exposures could increase susceptibility to infections given equal levels of exposure.” (1)

The CDC notes that “In the United States, as many as 95% of adults between 35 and 40 years of age have been infected.” And, “When infection with EBV occurs during adolescence or young adulthood, it causes infectious mononucleosis 35% to 50% of the time.” (2)

EBV establishes a lifelong dormant (latent) infection in some cells of the body's immune system and can lead to various diseases over time. How can an infected person help prevent the latent EBV from causing problems later in life?

polyDNA recommends that individuals concerned about the risk of EBV infection stop smoking. In addition, because EBV is so common, everyone should consider using Gene-Eden-VIR, a natural anti-EBV remedy, to boost the immune system against the latent virus.

Gene-Eden-VIR recently underwent a post marketing clinical study in which 70% of Gene-Eden-VIR users reported a reduction in viral symptoms.(3) The results of this study can seen here: http://www.cbcd.net/Gene-Eden-VIR-Clinical-Study.php

The key to your health is to reduce the level of latent viruses in your body to harmless levels.” – Dr. Hanan Polansky

To learn more about Gene-Eden-VIR and the Epstein Barr Virus, visit: http://gene-eden-kill-virus.com/EBV.php

References:

(1)    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661547/
(2)    http://www.cdc.gov/ncidod/diseases/ebv.htm
(3)    http://www.cbcd.net/Gene-Eden-VIR-Clinical-Study.php

###

polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

polyDNA developed Gene-Eden-VIR, an antiviral natural remedy that helps the immune system kill latent viruses.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10949092.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. New Study: Alcohol Drinkers May Face Long Term Health Issues
2. Beaumont Study: Nerve Stimulation Helps with Overactive Bladder
3. Study: Ipilimumab Shows Durable Responses But Low Overall Response Rate In Patients With Unresectable Or Metastatic Mucosal Melanoma
4. A pan-European study: Signs of motor disorders can appear years before disease manifestation
5. Study: Older Whooping Cough Vaccine More Effective
6. Study: Peer-referral programs can increase HIV-testing in emergency departments
7. Study: Patient openness to research can depend on race and sex of study personnel
8. Study: Brain makes call on which ear is used for cell phone
9. Study: HIV Infection Does Not Adversely Affect Outcomes of Liver Transplantation for Hepatocellular Carcinoma
10. Penn pilot study: Group of Bradford Co, Pa. residents concerned about health effects of hydrofracking
11. Great HealthWorks, Inc., makers of Omega XL, Report New Independent Study: Omega-3 DHA Protects Against Liver Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... As health ... medicine known as “patient engagement.” The patient is doing more than filling out a ... , “There is an increasing emphasis in health care and research on the ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along ... updates for the primary prevention of cardiovascular diseases during the 15th Annual ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Ellevate Network, ... in business to advocate for action towards gender equality at their inaugural Summit in ... around the globe, and reached a social audience of over 3 million. To watch ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Oct. 12, 2017 AVACEN Medical , Inc. ... with their  2017 New Product Innovation Award for Its ... primary and secondary medical device market research by Frost & ... first-to-market OTC, drug-free pain relief product, the AVACEN 100, offers ... treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... , Oct. 12, 2017 West Pharmaceutical ... innovative solutions for injectable drug administration, today announced that ... market opens on Thursday, October 26, 2017, and will ... and business expectations at 9:00 a.m. Eastern Time. To ... 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
Breaking Medicine Technology: